FDA Clearance Tracker · P160007
Guardian Connect system
Last checked: Nov 19, 2026Latest source record: Mar 8, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Mar 8, 2018
Approved
Time to decision
730 days
Received Mar 8, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160007
- Device name
- Guardian Connect system
- Applicant
- Medtronic Minimed
- Applicant location
- Northridge, CA
- Received
- Mar 8, 2016
- Decided
- Mar 8, 2018
- Decision
- Approved
- Supplements
- 55 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Sensor, glucose, invasive (MDS)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Guardian Connect system.The Guardian Connect system is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The Guardian Connect system provides real-time glucose values and trends through a Guardian Connect app installed on a compatible consumer electronic mobile device. It allows users to detect trends and track patterns in glucose concentrations. The Guardian Connect app alerts if a Guardian Sensor (3) glucose level reaches, falls below, rises above, or is predicted to surpass set values. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).The Guardian Connect system is comprised of the following devices: Guardian Connect app, Guardian Sensor (3), and the Guardian Connect transmitter.Guardian Sensor (3):The Guardian Sensor (3) is intended for use with Medtronic Diabetes glucose-sensing systems, to continuously monitor glucose levels in persons with diabetes. The Guardian Sensor (3) is indicated for 7 days of continuous use. It is indicated for use as an adjunctive device to complement, not replace, information obtained from standard blood glucose monitoring devices. The sensor is intended for single use and requires a prescription. Guardian Connect Transmitter:The Guardian Connect transmitter is intended for use with the Guardian Connect system. The Guardian Connect transmitter powers the glucose sensor, collects and calculates sensor data, and sends the data via Bluetooth version 4.0 to the Guardian Connect app installed on a compatible mobile device. The transmitter is only compatible with the Guardian Sensor (3). The transmitter is indicated for multiple uses on a single patient as a component of the Guardian Connect system.The Guardian Connect transmitter requires a prescription. Guardian Connect App:The Guardian Connect app is intended for use only by patients using a compatible mobile device, and who have sufficient experience to adjust mobile device audio and notification settings. The app displays sensor glucose data, and also provides a user interface for sensor calibration, entering data such as exercise and meals, and uploading information to the CareLink Personal website. It allows users to detect trends and track patterns in glucose concentrations. The Guardian Connect app provides alerts if a Guardian Sensor (3) glucose level reaches, falls below, rises above, or is predicted to surpass set values.The Guardian Connect app is available over-the-counter (OTC) but requires the Guardian Sensor (3) and Guardian Connect transmitter to function.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MDS. The earliest in FDA's data is P980022, decided Jun 15, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Medtronic Minimed
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261962 · Decided Jul 9, 2026 · 28 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
- MiniMed Flex pump510(k)
K253743 · Decided Mar 12, 2026 · 108 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
K253701 · Decided Feb 3, 2026 · 71 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.